HER2 + metastatic breast cancerTreatmentDrug resistanceNew drugsMetastatic HER2+breast cancer is an expanding area of drug development and research, with three new drugs approved in 2020 alone. While first-line therapy is well-established for metastatic HER2+breast cancer, the standard of care ...
[11]Skidmore L,Sakamuri S,Knudsen NA,et al.ARX788,a Site-specific Anti-HER2 Antibody-Drug Conjugate,Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers.Mol Cancer Ther.2020 Sep;19(9):1833...
Genomic studies have identified distinct breast cancer subtypes with differences in survival and response to therapy, including luminal A, luminal B, basal-like, HER2+ and Claudin-low subtypes1,2. HER2 overexpression leads to aggressive cancer phenotype and poor patient survival. Trastuzumab, a humani...
BioDrugs. 2008;22:315–29. Article CAS PubMed Google Scholar Massicano AVF, Lee S, Crenshaw BK, Aweda TA, El Sayed R, Super I, et al. Imaging of HER2 with [(89)Zr]pertuzumab in response to T-DM1 therapy. Cancer Biother Radiopharm. 2019;34:209–17. CAS PubMed PubMed Central ...
Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2...
Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2...
Various anti-HER2 therapies, including trastuzumab, pertuzumab, trastuzumab-deruxtecan, zanidatamab and neratinib, have undergone investigation. The objective of this review is to summarize the current evidence and outline future directions of targeted HER2 treatment therapy in patients with biliary tract...
targeted agents. In fact, trastuzumab is the only HER2?targeted therapy approved for gastric cancer and there are no approved HER2-targeted therapies for other types of cancer that are driven by the HER2 receptor. ZW25 has been well tolerated to date, which should allow it to be used in ...
Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2...
"With the advent of anti-HER2 therapy inmetastatic colorectal cancer, the key question for HER2-amplified RAS/BRAF wild-type tumors is who should be preferentially treated with therapy directed against HER2 vis-à-vis EGFR," said lead author and S1613 study chair Kanwal Raghav, MD, MBBS, an...